HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Shizuya Yamashita Selected Research

Xanthomatosis (Xanthoma)

6/2022Factors Associated with Carotid Atherosclerosis and Achilles Tendon Thickness in Japanese Patients with Familial Hypercholesterolemia: A Subanalysis of the Familial Hypercholesterolemia Expert Forum (FAME) Study.
5/2022Effectiveness and Safety of Lipid-Lowering Drug Treatments in Japanese Patients with Familial Hypercholesterolemia: Familial Hypercholesterolemia Expert Forum (FAME) Study.
8/2021Diagnosis and Management of Sitosterolemia 2021.
2/2021Probucol Trial for Secondary Prevention of Atherosclerotic Events in Patients with Coronary Heart Disease (PROSPECTIVE).
11/2018Cholesteryl ester transfer protein: An enigmatic pharmacology - Antagonists and agonists.
8/2018Guidelines for Diagnosis and Treatment of Familial Hypercholesterolemia 2017.
6/2018Guidance for Pediatric Familial Hypercholesterolemia 2017.
6/2016Rationale and Design of the PROSPECTIVE Trial: Probucol Trial for Secondary Prevention of Atherosclerotic Events in Patients with Prior Coronary Heart Disease.
8/2015Did we abandon probucol too soon?
9/2013[Primary hyperchylomicronemia].
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Shizuya Yamashita Research Topics

Disease

41Atherosclerosis
10/2020 - 01/2002
26Cardiovascular Diseases (Cardiovascular Disease)
08/2022 - 05/2002
24Hypertriglyceridemia
02/2022 - 01/2004
23Dyslipidemias (Dyslipidemia)
09/2021 - 03/2005
22Coronary Artery Disease (Coronary Atherosclerosis)
08/2022 - 01/2004
19Hyperlipoproteinemia Type II (Familial Hypercholesterolemia)
08/2022 - 01/2004
18Hyperlipidemias (Hyperlipidemia)
11/2020 - 05/2002
15Xanthomatosis (Xanthoma)
06/2022 - 08/2005
14Coronary Disease (Coronary Heart Disease)
02/2021 - 04/2003
10Type 2 Diabetes Mellitus (MODY)
11/2020 - 09/2008
8Inborn Genetic Diseases (Disease, Hereditary)
05/2022 - 09/2002
8Cholesteryl Ester Transfer Protein Deficiency
03/2019 - 07/2002
8Insulin Resistance
11/2018 - 05/2003
8Metabolic Syndrome (Dysmetabolic Syndrome X)
02/2017 - 12/2006
6Hypertension (High Blood Pressure)
05/2022 - 01/2004
6Tangier Disease
08/2021 - 08/2002
6Obesity
02/2017 - 01/2005
5Cardiomyopathies (Cardiomyopathy)
01/2022 - 01/2013
5Inflammation (Inflammations)
10/2019 - 01/2012
5Hyperlipoproteinemia Type III (Broad Beta Disease)
02/2017 - 06/2003
5Platelet Glycoprotein IV Deficiency
01/2012 - 05/2003
4Myocardial Infarction
02/2022 - 01/2012
4Fibrosis (Cirrhosis)
01/2022 - 01/2013
4Hypercholesterolemia
05/2019 - 09/2010
4Drug-Related Side Effects and Adverse Reactions
06/2018 - 01/2016
3Fatty Liver
01/2022 - 02/2002
3Sitosterolemia
08/2021 - 09/2010
3Stroke (Strokes)
06/2020 - 01/2019
3Chronic Renal Insufficiency
06/2020 - 09/2010
3Body Weight (Weight, Body)
02/2018 - 01/2015
3Hypothyroidism
02/2017 - 11/2009
3Hyperlipoproteinemia Type I (Lipoprotein Lipase Deficiency, Familial)
09/2013 - 09/2008
3ST Elevation Myocardial Infarction
01/2012 - 05/2010
2Diabetes Mellitus
12/2022 - 01/2004
2Carotid Artery Diseases
06/2022 - 11/2005
2Pancreatitis
11/2020 - 09/2013
2Liver Diseases (Liver Disease)
01/2020 - 02/2011
2Cardiomegaly (Heart Hypertrophy)
01/2020 - 01/2019
2Metabolic Diseases (Metabolic Disease)
01/2020 - 05/2019
2Heart Failure
10/2019 - 01/2013
2Hypoxia (Hypoxemia)
10/2019 - 10/2002
2Hyperglycemia
06/2018 - 05/2009
2Coronary Stenosis (Coronary Artery Stenosis)
02/2017 - 09/2012
2Hyperlipoproteinemia Type V
09/2013 - 01/2012

Drug/Important Bio-Agent (IBA)

34oxidized low density lipoproteinIBA
06/2022 - 10/2002
29Lipoproteins (Lipoprotein)IBA
08/2022 - 05/2003
27LipidsIBA
08/2022 - 01/2002
25LDL CholesterolIBA
06/2022 - 01/2002
24CholesterolIBA
01/2022 - 01/2002
20HDL CholesterolIBA
05/2022 - 07/2002
19Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA
12/2022 - 05/2002
17(R)-2-(3-((benzoxazol-2-yl-d4 (3- (4- methoxyphenoxy- d7)propyl)amino)methyl)phenoxy) butanoic acidIBA
02/2022 - 01/2018
17Triglycerides (Triacylglycerol)IBA
01/2021 - 09/2005
16LDL Lipoproteins (beta Lipoproteins)IBA
06/2022 - 01/2004
16HDL LipoproteinsIBA
08/2021 - 08/2002
16Apolipoprotein B-48IBA
02/2017 - 06/2003
10Probucol (Lorelco)FDA Link
06/2022 - 11/2005
9ChylomicronsIBA
02/2017 - 06/2007
8ApolipoproteinsIBA
08/2022 - 02/2002
7Glucose (Dextrose)FDA LinkGeneric
01/2021 - 05/2007
7Cholesterol Ester Transfer ProteinsIBA
03/2019 - 07/2002
7Proteins (Proteins, Gene)FDA Link
03/2019 - 01/2004
7AdiponectinIBA
01/2015 - 03/2005
6Ezetimibe (Zetia)FDA Link
01/2019 - 09/2010
6LDL Receptors (LDL Receptor)IBA
06/2018 - 10/2002
6Fenofibrate (CiL)FDA LinkGeneric
06/2018 - 06/2010
6Chylomicron RemnantsIBA
02/2017 - 06/2007
5Pharmaceutical PreparationsIBA
05/2022 - 11/2009
5Apolipoproteins E (ApoE)IBA
01/2018 - 08/2003
4AntioxidantsIBA
02/2021 - 12/2008
4Peroxisome Proliferator-Activated Receptors (PPAR)IBA
01/2021 - 01/2018
4Fibric Acids (Fibrates)IBA
01/2020 - 08/2003
4Apolipoprotein A-I (Apolipoprotein A1)IBA
10/2008 - 08/2005
3Lipoprotein(a)IBA
08/2022 - 09/2008
3gamma-sitosterol (beta-sitosterol)IBA
08/2021 - 09/2010
3ProgranulinsIBA
01/2020 - 10/2013
3Adenosine Triphosphate (ATP)IBA
01/2019 - 08/2002
3Insulin (Novolin)FDA Link
01/2019 - 01/2015
3Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
09/2015 - 03/2005
3Niacin (Nicotinic Acid)FDA LinkGeneric
05/2015 - 04/2012
3Hypolipidemic Agents (Antihyperlipidemics)IBA
01/2012 - 05/2002
2Phytosterols (Plant Sterols)IBA
08/2021 - 09/2010
2evolocumabIBA
11/2020 - 01/2014
2campesterolIBA
05/2020 - 09/2010
2Unsaturated Fatty Acids (Polyunsaturated Fatty Acids)IBA
01/2020 - 02/2017
2Omega-3 Fatty Acids (Omega 3 Fatty Acids)IBA
01/2020 - 02/2017
2Complement System Proteins (Complement)IBA
01/2020 - 03/2019
2Apolipoprotein C-IIIIBA
03/2019 - 03/2005
2Dipeptidyl-Peptidase IV InhibitorsIBA
06/2018 - 02/2017
2Fatty Acids (Saturated Fatty Acids)IBA
02/2017 - 05/2003
2DiglyceridesIBA
02/2017 - 04/2012
2Bile Acids and Salts (Bile Acids)IBA
01/2016 - 09/2010
2MK-0524IBA
05/2015 - 01/2015
2Lipoprotein Lipase (Diacylglycerol Lipase)IBA
09/2013 - 01/2012
2Apolipoproteins B (ApoB)IBA
10/2012 - 09/2005
2Biomarkers (Surrogate Marker)IBA
09/2012 - 07/2011

Therapy/Procedure

16Therapeutics
02/2022 - 08/2010
5Secondary Prevention
02/2021 - 05/2002
3Drug Therapy (Chemotherapy)
01/2016 - 09/2010
2Ligation
10/2019 - 01/2013